Xencor Inc
NASDAQ:XNCR

Watchlist Manager
Xencor Inc Logo
Xencor Inc
NASDAQ:XNCR
Watchlist
Price: 16.81 USD -4.92%
Market Cap: 1.2B USD

Xencor Inc
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Xencor Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Xencor Inc
NASDAQ:XNCR
Tax Provision
-$1.6m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Tax Provision
$735m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Tax Provision
-$1.8B
CAGR 3-Years
-13%
CAGR 5-Years
-28%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Tax Provision
-$1.2B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Tax Provision
-$773.6m
CAGR 3-Years
-1%
CAGR 5-Years
-29%
CAGR 10-Years
-37%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Tax Provision
-$567.1m
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
1%
No Stocks Found

Xencor Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Xencor Inc. is an innovative biotechnology company, distinguished by its commitment to harnessing the power of engineered monoclonal antibodies to fight complex diseases, especially within the realms of cancer and autoimmune disorders. Founded in 1997 and headquartered in Monrovia, California, Xencor relies on its proprietary XmAb technology platform – a sophisticated approach that enhances the structure and function of monoclonal antibodies to improve therapeutic performance. This technology enables Xencor to develop antibodies that are more potent, stable, and precise, ultimately driving their efficacy in targeting particular cellular mechanisms associated with disease progression while minimizing side effects. By focusing on core biological processes, Xencor leverages its platform to innovate new therapies that offer significant improvements over existing treatments, making it a nimble player in the competitive biotech landscape. Xencor's business model hinges on a dual strategy of internal drug development and strategic collaborations. Internally, Xencor is advancing a robust pipeline of drug candidates aimed at addressing various unmet medical needs, many of which are in various stages of clinical trials. These in-house projects are crucial for establishing the company's reputation as a leader in antibody engineering. In parallel, Xencor partners with larger pharmaceutical companies, licensing its XmAb technology and co-developing drugs—a model that provides a steady revenue stream from milestone payments, royalties, and research support. This hybrid approach not only diversifies Xencor's risk portfolio but also enhances its financial resilience, enabling a sustainable path to growth amidst the volatile biotech sector. Through this innovative framework, Xencor is poised to continue its influence in the biopharmaceutical industry, driven by a mission to bring transformative therapies to patients in need.

XNCR Intrinsic Value
13.31 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Xencor Inc's Tax Provision?
Tax Provision
-1.6m USD

Based on the financial report for Sep 30, 2025, Xencor Inc's Tax Provision amounts to -1.6m USD.

What is Xencor Inc's Tax Provision growth rate?
Tax Provision CAGR 3Y
-14%

Over the last year, the Tax Provision growth was 73%. The average annual Tax Provision growth rates for Xencor Inc have been -14% over the past three years .

Back to Top